C4 Therapeutics Inc (NASDAQ: CCCC) is 3.19% higher on its value in year-to-date trading and has touched a low of $1.06 and a high of $11.88 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The CCCC stock was last observed hovering at around $5.87 in the last trading session, with the day’s loss setting it -0.04%.
Currently trading at $5.83, the stock is -4.02% and -0.43% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.15 million and changing -0.68% at the moment leaves the stock -3.68% off its SMA200. CCCC registered 118.35% gain for a year compared to 6-month loss of -46.95%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -2.75% gain in the last 1 month and extending the period to 3 months gives it a 17.78%, and is -8.48% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.89% over the week and 7.76% over the month.
C4 Therapeutics Inc (CCCC) has around 145 employees, a market worth around $404.25M and $29.38M in sales. Profit margin for the company is -367.17%. Distance from 52-week low is 450.00% and -50.93% from its 52-week high. The company has generated returns on investments over the last 12 months (-34.80%).
C4 Therapeutics Inc quarterly earnings per share for the current quarter are estimated at -0.38 with sales reaching $4.6M over the same period.The EPS is expected to grow by 46.58% this year, but quarterly earnings will post 37.00% year-over-year. Quarterly sales are estimated to shrink -15.80% in year-over-year returns.
148.0 institutions hold shares in C4 Therapeutics Inc (CCCC), with institutional investors hold 100.11% of the company’s shares. The shares outstanding are 60.47M, and float is at 57.28M with Short Float at 18.34%. Institutions hold 88.44% of the Float.
The top institutional shareholder in the company is LYNX1 CAPITAL MANAGEMENT LP with over 6.88 million shares valued at $31.79 million. The investor’s holdings represent 9.9993 of the CCCC Shares outstanding. As of 2024-06-30, the second largest holder is RA CAPITAL MANAGEMENT, L.P. with 4.88 million shares valued at $22.54 million to account for 7.0891 of the shares outstanding. The other top investors are WASATCH ADVISORS LP which holds 4.85 million shares representing 7.0442 and valued at over $22.39 million, while BLACKROCK INC. holds 6.6146 of the shares totaling 4.55 million with a market value of $21.03 million.
